Compare · DFTX vs PAVS
DFTX vs PAVS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Paranovus Entertainment Technology Ltd. (PAVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PAVS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 1616.3x PAVS ($2.8M).
- DFTX has hit the wire 11 times in the past 4 weeks while PAVS has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 0 for PAVS).
- Company
- Definium Therapeutics Inc.
- Paranovus Entertainment Technology Ltd.
- Price
- -
- -
- Market cap
- $4.60B
- $2.8M
- 1M return
- -17.01%
- -
- 1Y return
- +135.57%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 0
- Recent ratings
- 8
- 0
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest PAVS
- SEC Form 20-F filed by Paranovus Entertainment Technology Ltd.
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.
- SEC Form NT 20-F filed by Paranovus Entertainment Technology Ltd.
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.
- Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.
- SEC Form 424B5 filed by Paranovus Entertainment Technology Ltd.
- PAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrants
- Beyond Fast Fashion: Advanced Fibers and Smart Manufacturing Are Reshaping the Global Textile Industry
- SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.